Lantheus Holdings Earnings Call Transcripts
Fiscal Year 2026
-
The company is executing a strategic transition to new products like PYLARIFY TruVu and Neuraceq, with a focus on operational efficiency, portfolio expansion, and market access. Revenue is expected to stabilize in 2026, with significant growth potential in Alzheimer's diagnostics and NET imaging as new approvals and reimbursement changes take effect.
-
Management outlined a strategic pivot to diagnostics, highlighted operational milestones for new product launches, and provided detailed financial guidance. The Alzheimer's franchise is positioned for growth with next-generation agents, while capital allocation remains disciplined amid ongoing litigation and market evolution.
Fiscal Year 2025
-
Full-year 2025 revenue grew slightly to $1.546 billion, with strong Q4 results and key acquisitions expanding the radiodiagnostic portfolio. 2026 guidance anticipates $1.4–$1.45 billion in revenue, EPS of $5.00–$5.25, and major new product launches expected to drive growth from 2027.
-
Q3 revenue grew 1.4% to $384M, with PYLARIFY sales down 7.4% but volumes up. Guidance for 2025 revenue and EPS was narrowed to the higher end, reflecting stabilization in key markets and ongoing product expansion. Leadership transitions and recent acquisitions position for future growth.
-
Nuclear medicine leadership is reinforced by product innovation, strategic acquisitions, and a robust pipeline targeting oncology and neurology. New product launches and a focus on Alzheimer's, along with disciplined capital allocation and integration, are set to drive growth and margin expansion.
-
Q2 2025 results missed expectations, with revenue and EPS guidance lowered due to competitive pressures and pricing challenges in the PSMA PET market. Strategic acquisitions and a new PYLARIFY formulation aim to diversify revenue and restore growth, while a $400M share repurchase reflects confidence in long-term prospects.
-
Strong sales from PYLARIFY and DEFINITY underpin growth, with new launches and acquisitions expanding the pipeline. Double-digit revenue growth is targeted for 2026, supported by innovative Alzheimer's and oncology diagnostics and therapeutics, and a robust financial position.
-
Strong growth in PSMA PET imaging is driven by PYLARIFY and expanding radioligand therapy adoption, with market stabilization expected after recent reimbursement changes. Strategic acquisitions and divestitures are streamlining operations, while the pipeline advances in Alzheimer's diagnostics and oncology.
-
Q1 2025 revenue grew 0.8% to $372.8M, with Pylarify and Definity sales stable but margin pressured by reimbursement and supply issues. Strategic acquisitions and the SPECT divestiture position the company for double-digit growth in 2026, with a robust pipeline in oncology and neurology.
-
Panelists discussed the clinical, logistical, and supply chain considerations for radiopharma isotopes, highlighting the strengths and limitations of F-18, gallium-68, copper-64, and emerging alpha emitters like lead-212 and terbium-161. Supply chain maturity, investment in infrastructure, and evolving healthcare models are key to meeting future demand.
-
Management outlined a strategy for double-digit growth from 2026, driven by Pylarify, Definity, and a robust pipeline including Alzheimer’s and oncology diagnostics. Key acquisitions and late-stage assets are expected to diversify revenue and strengthen market leadership.
-
Strong financials and a robust pipeline support double-digit growth targets for 2025 and beyond. Pylarify's commercial success and new neuro and oncology assets drive diversification, while strategic acquisitions and superior imaging capabilities reinforce market leadership.
-
The acquisition brings advanced manufacturing, a robust pipeline, and a skilled team, supporting expansion into radiopharmaceuticals and enabling commercial and operational synergies. The $250M upfront deal, plus milestones, is expected to be accretive within 18 months post-close.
-
The acquisition accelerates entry into the Alzheimer's radiodiagnostic market, adds a commercialized product and innovative pipeline, and is expected to be accretive to earnings within a year. The deal leverages operational synergies, global infrastructure, and positions the company for long-term growth in a rapidly expanding market.
Fiscal Year 2024
-
2024 saw record revenue and cash flow, with Pylarify surpassing $1B in sales and Definity delivering double-digit growth. Strategic acquisitions and CMS reimbursement changes position the company for continued expansion and double-digit growth from 2026.
-
The company leverages decades of radiopharma expertise, robust financials, and a diversified pipeline to drive growth in large, expanding markets. Strategic pricing, new contracts, and a $250 million buyback support long-term value, while regulatory changes and competitive dynamics shape future opportunities.
-
Q3 2024 saw 18.4% revenue growth, led by Pylarify and Definity, with strong margins and cash flow. CMS's new rule secures Pylarify reimbursement for 2025, and guidance was narrowed upward. Strategic partnerships and pipeline advances position the company for sustained growth.
-
PYLARIFY is achieving blockbuster status, with a robust pipeline in neurology and oncology. Strategic focus is on expanding early-stage assets, optimizing isotope selection, and maintaining leadership through superior clinical performance and supply reliability.
-
The company is expanding its radiopharmaceutical portfolio through disciplined M&A, with PYLARIFY driving strong commercial growth and new assets targeting oncology and Alzheimer's. Regulatory wins and robust financials support continued investment and pipeline expansion.
-
Q2 2024 saw 22.5% revenue growth, led by PYLARIFY and DEFINITY, with strong cash flow and expanded pipeline through strategic acquisitions. Full-year guidance was affirmed, with adjusted EPS revised to $6.60–6.70 due to increased R&D.
-
A leading radiopharmaceutical company leverages decades of expertise to ensure robust supply chains, regulatory compliance, and rapid product launches. Strategic isotope selection, advanced manufacturing, and a focus on neurology drive innovation and market leadership.
-
A leading radiopharmaceutical company is driving growth through PYLARIFY and DEFINITY, with a robust pipeline including late-stage therapeutics and Alzheimer's diagnostics. Strategic partnerships, market expansion, and proactive reimbursement strategies support long-term leadership.